JP2006509748A5 - - Google Patents

Download PDF

Info

Publication number
JP2006509748A5
JP2006509748A5 JP2004552660A JP2004552660A JP2006509748A5 JP 2006509748 A5 JP2006509748 A5 JP 2006509748A5 JP 2004552660 A JP2004552660 A JP 2004552660A JP 2004552660 A JP2004552660 A JP 2004552660A JP 2006509748 A5 JP2006509748 A5 JP 2006509748A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
heteroaryl
heterocyclyl
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004552660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006509748A (ja
Filing date
Publication date
Priority claimed from FR0214443A external-priority patent/FR2847253B1/fr
Application filed filed Critical
Publication of JP2006509748A publication Critical patent/JP2006509748A/ja
Publication of JP2006509748A5 publication Critical patent/JP2006509748A5/ja
Pending legal-status Critical Current

Links

JP2004552660A 2002-11-19 2003-11-19 Gsk−3ベータ阻害剤としてのピリダジノン誘導体 Pending JP2006509748A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0214443A FR2847253B1 (fr) 2002-11-19 2002-11-19 Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
PCT/EP2003/012950 WO2004046117A1 (en) 2002-11-19 2003-11-19 Pyridazinone derivatives as gsk-3beta inhibitors

Publications (2)

Publication Number Publication Date
JP2006509748A JP2006509748A (ja) 2006-03-23
JP2006509748A5 true JP2006509748A5 (enExample) 2006-12-28

Family

ID=32187711

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004552660A Pending JP2006509748A (ja) 2002-11-19 2003-11-19 Gsk−3ベータ阻害剤としてのピリダジノン誘導体

Country Status (19)

Country Link
EP (2) EP1611121B1 (enExample)
JP (1) JP2006509748A (enExample)
KR (1) KR20050083918A (enExample)
CN (1) CN1741999A (enExample)
AR (2) AR042089A1 (enExample)
AT (2) ATE368651T1 (enExample)
AU (2) AU2003283414A1 (enExample)
BR (1) BR0316720A (enExample)
CA (2) CA2506022A1 (enExample)
CO (1) CO5700722A2 (enExample)
DE (2) DE60315354T2 (enExample)
FR (1) FR2847253B1 (enExample)
MA (1) MA27814A1 (enExample)
MX (1) MXPA05005270A (enExample)
NO (1) NO20052887L (enExample)
PL (1) PL376129A1 (enExample)
RU (1) RU2005119151A (enExample)
TW (2) TW200503727A (enExample)
WO (2) WO2004046130A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176437A1 (en) 2001-08-31 2003-09-18 D.M. Watterson Anti-inflammatory and protein kinase inhibitor compositions and related methods for downregulation of detrimental cellular responses and inhibition of cell death
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
DE102004010194A1 (de) * 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
EP1604988A1 (en) 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
EP1598348A1 (en) 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Novel pyridazinone derivatives as inhibitors of CDK2
MX2007003327A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa.
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
JP4958786B2 (ja) 2004-09-20 2012-06-20 ゼノン・ファーマシューティカルズ・インコーポレイテッド 複素環誘導体および治療薬としてのそれらの使用
MX2007003319A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como agentes terapeuticos.
EP2269610A3 (en) 2004-09-20 2011-03-09 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP1812408B1 (en) 2004-11-02 2013-10-09 Northwestern University Pyridazine compounds, compositions and methods
WO2006050359A2 (en) 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds and methods
BRPI0611187A2 (pt) 2005-06-03 2010-08-24 Xenon Pharmaceuticals Inc derivados aminotiazàis como inibidores da estearoil-coa desaturase humana
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007127474A2 (en) * 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
BRPI0710938A2 (pt) 2006-04-28 2012-06-26 Univ Northwestern formulações contendo compostos de piridazina para o tratamento de doenças neuroinflamatórias
WO2007127475A2 (en) * 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101537006B (zh) 2008-03-18 2012-06-06 中国科学院上海药物研究所 哒嗪酮类化合物在制备抗肿瘤药物中的用途
US9212146B2 (en) 2008-03-18 2015-12-15 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Substituted pyridazinones for the treatment of tumors
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
AU2012203023C1 (en) * 2009-03-02 2013-11-07 Novartis Ag N-(hetero)aryl, 2- (hetero)aryl-substituted acetamides for use as Wnt signaling modulators
UA103918C2 (en) * 2009-03-02 2013-12-10 Айерем Элелси N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
UY33469A (es) 2010-06-29 2012-01-31 Irm Llc Y Novartis Ag Composiciones y metodos para modular la via de señalizacion de wnt
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GB201201100D0 (en) * 2012-01-20 2012-03-07 Medical Res Council Polypeptides and methods
DK3290407T3 (da) 2013-10-18 2020-03-23 Celgene Quanticel Res Inc Bromodomæneinhibitorer
WO2015127137A1 (en) * 2014-02-19 2015-08-27 Aldea Pharmaceuticals, Inc. Mitochondrial aldehyde dehydrogenase 2 (aldh2) binding polycyclic amides and their use for the treatment of cancer
EA201892666A1 (ru) * 2016-05-25 2019-08-30 Байер Фарма Акциенгезельшафт 3-оксо-2,6-дифенил-2,3-дигидропиридазин-4-карбоксамиды
CN116531380B (zh) * 2017-02-09 2025-11-07 拜耳股份公司 用于治疗癌症的2-杂芳基-3-氧代-2,3-二氢哒嗪-4-甲酰胺
US11459312B2 (en) 2017-11-21 2022-10-04 Bayer Aktiengesellschaft Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides
AU2019318209B2 (en) 2018-08-10 2025-09-25 Diapin Therapeutics, Llc Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
CN111533697B (zh) * 2020-05-07 2023-03-31 成都大学 4-氨基哒嗪酮类化合物及其制备方法
CN111533735A (zh) * 2020-05-08 2020-08-14 张建蒙 氧代二氢哒嗪噻唑类衍生物及其在抗肿瘤药物中的应用
CN111393374A (zh) * 2020-05-08 2020-07-10 张建蒙 氧代二氢哒嗪类衍生物及其在抗肿瘤药物中的应用
WO2022113003A1 (en) 2020-11-27 2022-06-02 Rhizen Pharmaceuticals Ag Cdk inhibitors
WO2022149057A1 (en) 2021-01-05 2022-07-14 Rhizen Pharmaceuticals Ag Cdk inhibitors
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4134467A1 (de) * 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4127404A1 (de) * 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPH09216883A (ja) * 1996-02-09 1997-08-19 Fujisawa Pharmaceut Co Ltd ピラゾロピリジン化合物および該化合物を含有する医薬
WO1999034018A1 (en) * 1997-12-24 1999-07-08 The Regents Of The University Of California Methods of using chemical libraries to search for new kinase inhibitors
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
US6440959B1 (en) * 1999-04-21 2002-08-27 Hoffman-La Roche Inc. Pyrazolobenzodiazepines
CA2742411A1 (en) * 2000-09-18 2002-03-21 Eisai R&D Management Co., Ltd. Pyridazinone and triazinone compounds and use thereof as pharmaceutical preparations
EP1345925B1 (en) * 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors

Similar Documents

Publication Publication Date Title
RU2005119151A (ru) Производные пиридазинона в качестве gsk-3бета-ингибиторов
AU2019201179B2 (en) Therapeutically active compounds and their methods of use
ES2500165T3 (es) Composiciones de biarilo y métodos para modular una cascada de quinasas
US10329274B2 (en) Indole carboxamide compounds
CA2396590A1 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
AU2011249167B2 (en) Picolinamide and pyrimidine-4-carboxamide compounds, process for preparing and pharmaceutical composition comprising the same
US8536165B2 (en) Azabiphenylaminobenzoic acid derivatives as DHODH inhibitors
JP2018530571A5 (enExample)
CN105593215B (zh) 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2004026841A1 (ja) 新規6−置換ウラシル誘導体及びアレルギー性疾患の治療剤
TW200413334A (en) Diaminotriazoles useful as inhibitors of protein kinases
KR20150096794A (ko) 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물
JP2008516902A5 (enExample)
JP2009526072A5 (enExample)
NZ532373A (en) Pyrimidine compound and medicinal composition thereof
RU2002121645A (ru) Производные 2-аминоникотинамида и их применение в качестве ингибиторов vegf-рецептора тирозинкиназы
CA2463822A1 (en) Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors)
TW200412970A (en) Pharmaceutical composition comprising PDE 5 inhibitor and active ingredients
CN101537001A (zh) 作为jak-stat3信号通路抑制剂的化合物的应用
JP2012513398A5 (enExample)
RU2018131775A (ru) 6-арил-4-морфолин-1-илпиридоны, пригодные для лечения рака или диабета
CA2504907A1 (en) Indoles useful in the treatment of androgen-receptor related diseases
JP2021520340A5 (enExample)
JP2019505594A5 (enExample)
WO1998013348A1 (en) Substituted vinylpyridine derivatives and drugs containing the same